- Featured Product
- KD/KO Validated
VEGFA Monoclonal antibody
VEGFA Monoclonal Antibody for IF, IHC, WB, ELISA
Host / Isotype
Mouse / IgG2b
Reactivity
Human and More (3)
Applications
WB, IHC, IF, ELISA
Conjugate
Unconjugated
CloneNo.
2E2H9
Cat no : 66828-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | MCF-7 cells, HUVEC cells, NCI-H1299 cells, A431 cells, SH-SY5Y cells, HuH-7 cells, T-47D cells, MDA-MB-231 cells |
Positive IHC detected in | human lung cancer tissue, human liver cancer tissue, human colon cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF detected in | MCF-7 cells, human lung cancer tissue |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:4000 |
Immunohistochemistry (IHC) | IHC : 1:400-1:1600 |
Immunofluorescence (IF) | IF : 1:200-1:800 |
Sample-dependent, check data in validation data gallery |
Published Applications
KD/KO | See 2 publications below |
WB | See 45 publications below |
IHC | See 9 publications below |
IF | See 5 publications below |
Product Information
66828-1-Ig targets VEGFA in WB, IHC, IF, ELISA applications and shows reactivity with Human samples.
Tested Reactivity | Human |
Cited Reactivity | human, rat, pig |
Host / Isotype | Mouse / IgG2b |
Class | Monoclonal |
Type | Antibody |
Immunogen | VEGFA fusion protein Ag13500 |
Full Name | vascular endothelial growth factor A |
Calculated molecular weight | 412 aa, 46 kDa |
Observed molecular weight | 43 kDa |
GenBank accession number | BC065522 |
Gene symbol | VEGFA |
Gene ID (NCBI) | 7422 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are associated with microvascular complications of diabetes type 1 (MVCD1). VEGFA has 17 isoforms with MW from 16 to 45 kDa. Some isoforms have homodimer forms (e.g.; VEGFA189 38kDa or VEFGA110 34kDa). VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids (PMID:15602010 ). This antibody can recognize all VEGFA isoforms.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for VEGFA antibody 66828-1-Ig | Download protocol |
IHC protocol for VEGFA antibody 66828-1-Ig | Download protocol |
IF protocol for VEGFA antibody 66828-1-Ig | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Am J Transl Res Dimethyl fumarate suppresses hepatocellular carcinoma progression via activating SOCS3/JAK1/STAT3 signaling pathway. | ||
Cancers (Basel) Targeting Angiogenesis by Blocking the ATM-SerRS-VEGFA Pathway for UV-Induced Skin Photodamage and Melanoma Growth. | ||
Med Sci Monit Hirudin Reduces the Expression of Markers of the Extracellular Matrix in Renal Tubular Epithelial Cells in a Rat Model of Diabetic Kidney Disease Through the Hypoxia-Inducible Factor-1α (HIF-1α)/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway. | ||
J Exp Clin Cancer Res MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. | ||
Aging (Albany NY) Exosomal circRNAs contribute to intestinal development via the VEGF signalling pathway in human term and preterm colostrum. | ||
Food Nutr Res The mechanism and candidate compounds of aged citrus peel (chenpi) preventing chronic obstructive pulmonary disease and its progression to lung cancer. |